Novo Nordisk plots phase 3 trials for next-gen obesity asset amycretin
Wegovy-maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early next year.
Wegovy-maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early next year.
